Clinical Trials

Are you a woman 18 years old or older who has been diagnosed with LAM? This study is examining whether long-term treatment with medicine called sirolimus can stop lung damage in women who have LAM. This study takes place at multiple locations in the United States.

DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 24-27 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.

The objective of this study is to investigate the mechanisms of respiratory functional and respiratory motor responses to the scES as an important step toward the long-term goal of developing effective evidence-based rehabilitation strategies for patients with SCI. The central hypothesis is that scES raises the excitability of motor networks for respiration resulting in amplified use-dependent neural plasticity in response to the respiratory training. The rationale for the proposed study is to justify the development of a new direction in respiratory rehabilitation by using respiratory training in combination with electrical spinal cord stimulation.

Do you live in Appalachian Kentucky? Researchers will be using a phone app and incentives to provide health coaching. Participants will be encouraged to eat more fruits and vegetables and reduce saturated fats and screen time. They will also monitor your physical activity using a motion device and help you become more active. To join, you must be 18 years or older. The study is taking place in Benham, Kentucky.

Are you interested in participating in clinical research about ultrasounds? Ultrasounds are one of the most common ways to take images of the inside of your body. In some cases, something called a contrast agent is injected through an IV to make your organs even more visible during the ultrasound. Researchers in this clinical trial are comparing a new type of contrast agent to the current type used in ultrasounds. Participants must be 19 years old and considered to be generally healthy. The study is taking place in Kansas City, Missouri, and Omaha, Nebraska.